Logo wahanariau.com
  2. Teva pharmaceutical

Teva pharmaceutical

Index
Globenewswire

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in Major Parts of Europe and in Israel

Senin, 13 Januari 2025 - 13:30:00 Wib
Globenewswire

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Selasa, 24 Desember 2024 - 11:36:00 Wib
Globenewswire

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Sabtu, 21 Desember 2024 - 11:20:28 Wib
Globenewswire

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Selasa, 17 Desember 2024 - 20:30:00 Wib
Globenewswire

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Rabu, 11 Desember 2024 - 20:07:02 Wib
Globenewswire

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Jumat, 06 Desember 2024 - 14:23:23 Wib
Globenewswire

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Rabu, 04 Desember 2024 - 14:30:00 Wib
Globenewswire

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Selasa, 26 November 2024 - 06:09:27 Wib
Globenewswire

Teva to Present at the Jefferies London Healthcare Conference

Sabtu, 09 November 2024 - 05:00:00 Wib
Globenewswire

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Sabtu, 02 November 2024 - 03:59:12 Wib
Globenewswire

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as Well as

Sabtu, 02 November 2024 - 03:58:04 Wib
Globenewswire

Teva Statement on European Commission Decision; Company to Appeal

Kamis, 31 Oktober 2024 - 18:30:00 Wib
Globenewswire

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Selasa, 22 Oktober 2024 - 18:30:00 Wib
Globenewswire

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Selasa, 08 Oktober 2024 - 18:30:00 Wib
Globenewswire

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Kamis, 03 Oktober 2024 - 20:00:00 Wib
Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Selasa, 01 Oktober 2024 - 18:31:45 Wib
Globenewswire

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Senin, 23 September 2024 - 12:30:00 Wib
Globenewswire

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

Sabtu, 21 September 2024 - 16:00:00 Wib
Globenewswire

Teva to Present at the Bank of America 2024 Global Healthcare Conference

Kamis, 12 September 2024 - 06:01:11 Wib
Globenewswire

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Selasa, 27 Agustus 2024 - 05:55:33 Wib
Globenewswire

Teva Announces Strong Growth in Second Quarter Revenues Mainly Driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance

Rabu, 31 Juli 2024 - 18:30:00 Wib